Search PubMed⌕ Search

Biomedical subjects

W Theiss

Publications and source records attributed to W Theiss.

At least 73 records · Page 4Linked to original sources

Repeated phlebographic examination during and after fibrinolytic therapy with streptokinase and urokinase.

Forty-three patients with deep vein thrombosis were given fibrinolytic therapy with streptokinase and/or urokinase. In all patients the diagnosis was made phlebographically, and repeat phlebography was performed after termination of therapy. Sixty-four of 104 vein segments initially occluded (62%) were partially or completely recanalized. No vein segments particularly suitable for fibrinolytic therapy could be defined. The therapy was as successful in cases in which the thrombosis extended over several segments as in those in which the occlusions involved only one or two segments. Similarly, there was no difference in the success rate for thrombi that were still freely floating and for thrombi that occluded the veins completely. It is recommended that fibrinolytic therapy be given in suitable cases in which clinical symptoms have persisted up to two weeks; in some cases this limit may even be extended up to one month.

Adult↗

[DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jürgens syndrome (author's transl)].

1-Deamino-8-D-arginine vasopressin (DDAVP), a vasopressin analogue, increases factor VIII levels in plasma. A female carrier of haemophilia A with known bleeding diathesis and markedly reduced factor VIII activity was successfully treated with DDAVP during bilateral Caldwell-Luc's operation for chronic maxillary sinusitis. An estimated 5000 U factor VIII concentrate was calculated to have been saved. DDAVP is the first alternative to replacement therapy in the treatment of moderate and mold forms of haemophilia A and von Willebrand's disease.

Arginine Vasopressin↗

[Fibrinolytic therapy in deep venous thrombosis of the upper and lower extremity].

Fibrinolytic therapy was carried out in 59 patients suffering from a total of 60 deep venous thromboses of the iliac segment (n = 24), the femoropopliteal segment (n = 18), the deep calf veins (n = 2), or the subclavian vein (n = 16). 46 patients received streptokinase (SK), 4 were given urokinase (UK), and 10 were treated with streptokinase followed by urokinase (SK + UK). The duration of fibrinolytic therapy was between 19 and 596 hours (x = 166 +/- 111 hrs). Phlebographic examination was used to determine the location of the thrombotic occlusion as well as to evaluate therapeutic results. To assure sufficient anticoagulatory protection during therapy with streptokinase the dose of streptokinase was either reduced by steps of 20,000 U/hr to a minimum of 40,000 U/hr or heparin was added as a continuous infusion. Urokinase was administered with a mean loading dose of 75,000 IU followed by an average maintenance dose of 40,000 IU/hr; it was always given in combination with heparin. When therapeutic success was graded as complete/partial/no recanalisation, the following results were obtained: thrombotic occlusion up to 1 week old 35%/48%/17%; up to 2 weeks old 57%/14%/29%; 3 or 4 weeks old 12%/38%/50%; older than 4 weeks 13%/37%/50%. The two most common side effects were a fall of the hemoglobin and a rise of body temperature. Treatment with SK had to be interrupted for bleeding in two cases. One patient diet after rupture of the liver and of the spleen following development of subcapsular hematoma in these organs, 3 patients survived pulmonary embolism without major long-term impairment. Considering medical and social aspects (preservation of capability for working in young adults) it appears justified to administer fibrinolytic agents up to a thrombus age of 14 days, in some cases even up to a thrombus age of 28 days. Good results in cases of deep vein thrombosis of the lower limbs are often obtained only when fibrinolytic therapy is extended beyond 96 hours. It should be performed in intensive care units only. Follow-up examinations of the venous drainage capacity up to 2 years after fibrinolytic therapy document the good therapeutic effect that is warrented by streptokinase or urokinase induced complete recanalisation.

Adolescent↗

Pulmonary embolisation of retained transvenous pacemaker electrode.

When removal of an endocardial pacemaker electrode became necessary in a patient with congestive myocardiopathy, it proved to be incarcerated. Therefore, a portion of it had to be left in site after cutting the external end of the pacing catheter. During follow-up examinations the electrode was seen to migrate in the large veins and finally was found embolized into a pulmonary artery. While there have been publications on the migration of retained pacemaker electrodes before, to our knowledge this represents the first case reported with pulmonary embolization of the migrating fragment.

Adult↗

[Dosage of long-term streptokinase fibrinolytic administration (author's transl)].

Using generalyy accepted dosage schedules during long-term fibrinolytic treatment with streptokinase, anticoagulatory protection against recurrent thromboses can no longer be guaranteed after two to three days, unless heparin is also administered. In contrast, no heparin was needed in 11 out of 13 patients on fibrinolytic treatment of at least five days when maintenance dose was adjusted in accordance with results of coagulation tests. In this way prolonged fibrinolysis was maintained together with adequate anticoagulation by circulating fibrin(ogen) breakdown products for the entire duration of streptokinase treatment. This required the gradual reduction of maintenance dose to between 40 000 U/h and 80 000 U/h in the majority of patients. This form of fibrinolytic treatment with individually adjusted dosages can be undertaken without undue strain on laboratory resources; the risk of haemorrhage is no higher than with the customary form using higher and constant maintenance doses.

Drug Therapy, Combination↗

[Measurement of electric impedance as a screening method for diagnosing haemorrhagic diatheses (author's transl)].

Changes in electrical impedance during blood clotting have been previously described. Personal measurements on blood of 18 healthy donors and 29 patients with various disorders of clotting gave reproducible results with this method. There was a marked difference between normal subjects and those with bleeding diatheses regardless of type. There was good correlation between impedance changes and the thrombelastogram, the former being more sensitive in diagnosing haemorrhagic disorders. Further studies are required to evaluate its place as a screening method in these conditions.

Blood Coagulation Disorders↗